Trial Profile
A randomized, double-blind, placebo controlled and active comparator study phase III trial of Deflazacort in Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2017
Price :
$35
*
At a glance
- Drugs Deflazacort (Primary) ; Prednisone
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Sponsors Marathon Pharmaceuticals
- 09 Feb 2017 According to a CureDuchenne Ventures media release, Marathon Pharmaceuticals company got the U.S. Food and Drug Administration approval for EMFLAZA™ (deflazacort) use in patients who are five years and older with Duchenne muscular dystrophy regardless of genetic mutation.
- 26 Aug 2016 Results assessing effects of Deflazacort and Prednisone on muscle strength and motor function published in the Neurology (2016).
- 21 Apr 2016 Results (post hoc subgroup analysis) assessing the effects of deflazacort and prednisone on pulmonary function presented at the 68th Annual Meeting of the American Academy of Neurology